Jazz Pharmaceuticals' Chief Commercial Officer Samantha Pearce Plans To Retire By June 30, 2027
Jazz plans a formal search for a successor, weighing internal and external candidates, an 8-K shows.
Samantha Pearce, Jazz Pharmaceuticals' Executive Vice President and Chief Commercial Officer, told the company on Tuesday that she intends to retire, according to an 8-K filed Friday. She will leave when a successor is selected and appointed or by June 30, 2027, whichever comes first.
What the 8-K says
The filing, made under Item 5.02 (the section covering departures of certain officers), reports that Pearce gave notice of her intent to retire on October 6, 2026. The retirement is tied to the earlier of two events: her successor being chosen and appointed, or June 30, 2027.
That date sets an outer limit on the handover. The filing was signed by Neena Patil, Executive Vice President and Chief Legal Officer, and dated Friday.
Jazz said it plans to start a formal search for Pearce's successor. The search will consider both internal and external candidates.
What it changes
Jazz now has a commercial chief who has announced her exit but has no named replacement. Her role continues until a successor is appointed or the June 30, 2027 date arrives.
If you own the stock, the share price at Thursday's close was $222.45, down 3.78% on the session, before the filing was disclosed Friday morning (market data). The filing does not tie that move to the retirement notice.
The next marker is the naming of Pearce's successor, with June 30, 2027 as the latest date she is set to leave.
Sources
- 8-K Filing — Jazz Pharmaceuticals plc (JAZZ) — SEC EDGAR
